Undisclosed PD-1 x VEGF x IL-2v triple-fusion protein / Mustbio, Celltrion - LARVOL DELTA

Celltrion–MustBio Collaborate on PD-1×VEGF×IL-2v Cancer Therapy [Google translation] (HIT News) - "Celltrion will lead the full development program—from preclinical studies and cell-line development to clinical trials, regulatory approvals, and commercialization. MustBio will apply its multi-antibody and IL-2 variant–based cytokine platforms to design and discover the candidate and carry out early-stage research, including initial animal efficacy tests. Celltrion will pay MustBio an upfront fee of $2.04 million."

Licensing / partnership • Oncology